Christophe Le Terrier

Impact of a restrictive antibiotic policy on the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an endemic region: a before-and-after, propensity-matched cohort study in a Caribbean intensive care unit

Christophe Le Terrier, Marco Vinetti, Paul Bonjean et al. · Critical Care · 2021 · 49 citations · Full text

<i>In vitro</i> activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing <i>Escherichia coli</i> clinical isolates

Christophe Le Terrier, Patrice Nordmann, Mustafa Sadek et al. · Journal of Antimicrobial Chemotherapy · 2023 · 46 citations · Full text

Preparedness and Reorganization of Care for Coronavirus Disease 2019 Patients in a Swiss ICU: Characteristics and Outcomes of 129 Patients

Steve Primmaz, Christophe Le Terrier, Noémie Suh et al. · Critical Care Explorations · 2020 · 40 citations · Full text

<i>In vitro</i> activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> producing metallo-β-lactamases

Christophe Le Terrier, Patrice Nordmann, Laurent Poirel · Journal of Antimicrobial Chemotherapy · 2022 · 36 citations

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

Christophe Le Terrier, Patrice Nordmann, Charlotte Freret et al. · Antimicrobial Agents and Chemotherapy · 2023 · 31 citations · Full text

Escherichia Coli, Antimicrobial Chemotherapy, Bacterial Pathogens +19